Medical Oddities: A spoonful of surgical trouble
-
By
-
Teraya Smith
-
November 18, 2026
-
6 min
By
Teraya Smith
November 18, 2026
According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.
July 14, 2026
Phase 3 findings showed longer median progression-free survival with zanidatamab-containing regimens vs trastuzumab plus chemotherapy.
August 25, 2026
Proteomic biomarkers improve short-term lung cancer risk assessment.
June 1, 2026